Form SC 13G/A Arcus Biosciences, Inc. Filed by: BlackRock, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Arcus Biosciences (RCUS) PT Raised to $46 at Citi
October 24, 2024 2:42 PM EDTCiti analyst Yigal Nochomovitz raised the price target on Arcus Biosciences (NYSE: RCUS) to $46.00 (from $38.00) while maintaining a Buy rating.
The analyst comments "The Triple data for cas, while still evolving, provide in our view a very favorable picture of clinical... More
BofA Securities Reiterates Neutral Rating on Arcus Biosciences (RCUS)
October 24, 2024 1:48 PM EDTBofA Securities analyst Jason Zemansky reiterated a Neutral rating and $22.00 price target on Arcus Biosciences (NYSE: RCUS).
The analyst comments "Arcus Q&A investor follow-up to this mornings presentation of the ARC-20 casdatifan (cas) at ENA didnt offer much in the way of new insights, in... More
